A charity says it is "disappointed" over a decision not to provide a life-extending breast cancer drug on the NHS. The National Institute for Health and Care Excellence concluded it could not be predicted how long pertuzumab extended people's lives.
A charity has expressed its "disappointment" over a decision not to provide a life-extending breast cancer drug on the NHS.
Breast Cancer Campaign said it hopes the draft decision from the National Institute for Health and Care Excellence (Nice) will be reversed before officials make a final determination on pertuzumab as a treatment for an advanced form of the disease.
The drug, also known as Perjeta, was widely welcomed when it was first introduced by manufacturers Roche.
The drug targets the HER-2 gene found in 20 percent of breast cancer patients. Trials have found that when used alongside the drug Herceptin and chemotherapy, patients live an average of six months longer without their cancer getting worse, compared with those just on Herceptin and chemotherapy.
At present, patients can access the drug through the Cancer Drugs Fund but it is not routinely available through the health service.
The Democratic presidential candidate may also have shown his cards on his choice of running mate.
The US president also shared a post on Twitter accusing Dr Anthony Fauci of misleading the public over hydroxychloroquine.
Fears over an impending second wave of coronavirus dominates Wednesday’s front pages.